MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH Share Price (EMER)
Here is the latest stock price and chart of Procter & Gamble Health. For more details, see the Procter & Gamble Health company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Nov 14, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)4,295.30 | Open (Rs) 4,340.00 | High (Rs) 4,396.00 | Low (Rs) 4,228.95 |
| % Change-0.35 | Volume 1,007 | Value (Rs) 4,343,532 | 52-Week H/L 5,120.80 / 2,785.10 |
| Live NSE Quotes | Nov 14, 2019 3:29:56 PM | ||
|---|---|---|---|
| Price (Rs)4,275.05 | Open (Rs) 4,306.00 | High (Rs) 4,395.00 | Low (Rs) 4,228.15 |
| % Change-0.73 | Volume 16,375 | Value (Rs) 70,652,066 | 52-Week H/L 5,050.00 / 2,100.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 80.74 | P/E Ratio (x) 53.20 | Market Cap (Rs m) 71,301.98 | P/BV (x) 4.63 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
Listen In: Our Investor Hour Podcast Connects You with the World's Most Successful Investors
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
PROCTER & GAMBLE HEALTH Share Price Today:
PROCTER & GAMBLE HEALTH last traded price was down 0.4% to Rs 4,295.3 on the BSE. On the NSE, PROCTER & GAMBLE HEALTH last traded price was down 0.7% to Rs 4,275.1. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.3%. And the benchmark S&P BSE SENSEX was at 40,286.5 (up 0.4%).
Over the last 30 days, the PROCTER & GAMBLE HEALTH share price is down 3.0%. And over the last one year, PROCTER & GAMBLE HEALTH share price is up 43.7%.
|
| |
Today's Market
Moody's Economic Growth Forecast, Rising Retail Inflation, and Top Cues in Focus Today(Pre-Open)
Indian share markets ended their day on a positive note yesterday. At the closing bell yesterday, the BSE Sensex stood higher by 170 points (up 0.4%).
Related Views On News
PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)
Nov 14, 2019 | Updated on Nov 14, 2019For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.
PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints? (Profit Hunter)
Nov 7, 2019Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?
These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound (Profit Hunter)
Nov 5, 2019How to avoid the most common investing mistake and make the most of the smallcap rebound.
Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks (The 5 Minute Wrapup)
Nov 8, 2019Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.
The Top Stocks for 2020 Pass This Most Critical Metric (The 5 Minute Wrapup)
Nov 5, 2019Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.
What to Buy at Sensex 40,000 (The 5 Minute Wrapup)
Nov 4, 2019Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?
MoreTRACK PROCTER & GAMBLE HEALTH
- Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON PROCTER & GAMBLE HEALTH
PROCTER & GAMBLE HEALTH - ACTAVIS COMPARISON
COMPARE PROCTER & GAMBLE HEALTH WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.